Ibio Inc IBIO

Healthcare Biotechnology

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

NYSEAM:IBIO - Post by User

Ibio Inc

Bullboard Posts

Comment by Covid19on Mar 21, 2020 10:15pm

240 Views

Post# 30834423

RE:IBIO🇺🇲usa or VXL🇨🇦cnd ? [C-19 Vaccine]

VAXIL BIO ! 111% hasn't even touched the $1 range yet. Here is the full World Health Organizations vaccine candidate list \/
<br /> <a href="https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1" class="BBLink" rel="nofollow noindex ugc noopener" target="_blank">https://www.who.int/blueprint/priority-diseases/key-action/novel-coronavirus-landscape-ncov.pdf?ua=1</a><br />

Bullboard Posts

Invest wiser with BMO's InvestorLine Platform features